]>

IRCT201201231241N3 IRCT 2012-03-01 Department of Research and Technology, Mazandaran University of Medical Sciences Comparison of Sequential therapy for eradication of H. Pylori infection in renal failure patients Comparison of Sequential therapy for eradication of H. Pylori infection in renal failure patients 2010-09-11 anticipated 80 Complete https://irct.ir/trial/454 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 2 Helicobacter pylori infection. Intervention 1: Intervention Group:Pantoprazul (BD40mg) and amoxicillin (If keratinize clearance is between 10-30:250-500mg BD and if it is less than 10:250-500 mg Daily)for 5 days and Then Pantoprazul (40mg BD) and clarithromycin (250 mg BD) and tinidazole (500mg BD) for 5 days. Intervention 2: Control Group : Pantoprazul (40mg BD) and Claritromicine(250 mg BD)and Amoxicillin (If Kratinize Cearance is between 10-30:250-500mg BD and if it is less than 10:250-500 mg Daily).

public Dr Atieh Makhlough

Internal ward, Emam Hospital, Amir Mazandarani Boulevard

ُSari Iran (Islamic Republic of) +98 15 1226 4047 dr.makhloogh@mazums.ac.ir , makhlough_a@yahoo.com Mazandaran University of Medical Sciences scientific Dr Atieh Makhlough

Internal ward, Emam Hospital, Amir Mazandarani Boulevard

Sari Iran (Islamic Republic of) +98 15 1226 4047 makhlough_a@yahoo.com Mazandaran University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Inclusion criteria: patients with dyspepsia symptoms over the past one month from gastroenterology or nephrology clinic or hospital dialysis ward who have infection with H. Pylori confirmed by rapid urease test and biopsy in endoscopy. Exclusion Criteria : taking antibiotic regimen to eradicate H. pyloriand or receiving proton pump inhibitors, Bismuth, or NSAID during the last month; concomitant anticoagulant, corticosteroid or Ketoconazole; history of gastric or esophageal surgery; sensitivity to antibiotics; negative endoscopic biopsy; drinking alcohol and smoking; pregnancy and lactation; severe heart disease; diseases of the thyroid gland or liver cancer; chronic renal failure patients who are prior to stage 5 or have not received renal replacement therapy. 20 years 75 years Both B98.0 Helicobacter pylori Treatment - Drugs Treatment - Drugs Intervention Group:Pantoprazul (BD40mg) and amoxicillin (If keratinize clearance is between 10-30:250-500mg BD and if it is less than 10:250-500 mg Daily)for 5 days and Then Pantoprazul (40mg BD) and clarithromycin (250 mg BD) and tinidazole (500mg BD) for 5 days Control Group : Pantoprazul (40mg BD) and Claritromicine(250 mg BD)and Amoxicillin (If Kratinize Cearance is between 10-30:250-500mg BD and if it is less than 10:250-500 mg Daily) Eradication of Helicobacter pylori Infection. Timepoint: At the end of four weeks after treatment. Method of measurement: Urea Test. Eradication of Helicobacter pylori Infection. Timepoint: At the end of four weeks after treatment. Method of measurement: Creatinine Clearance Test. Eradication of Helicobacter pylori Infection. Timepoint: At the end of four weeks after treatment. Method of measurement: Stool examination. Eradication of Helicobacter pylori Infection. Timepoint: At the end of four weeks after treatment. Method of measurement: Biopsy by Endoscopic. Acute Renal Failure. Timepoint: At the first and second weeks of treatment. Method of measurement: Testing Urea. Acute Renal Failure. Timepoint: At the first and second weeks of Treatment. Method of measurement: creatinine clearance test. Acute Renal Failure. Timepoint: at the first and second weeks of treatment. Method of measurement: weight. Department of Research and Technology, Mazandaran University of Medical Sciences Approved 2012-01-08 Mazandaran University of Medical Sciences Building No. 2 of University, Moallem Square Sari Iran (Islamic Republic of)